Ann: Proteomics International Webinar and Q&A, page-6

The sad reality is Richard should move into a scientific role, like a chief scientific officer.

He is a terrible communicator and I start to wonder if it's his inability to communicate clearly that has caused the concerns raised by MSAC.

Pre selected questions and no real-time dialogue with investors is poor form. Most stocks I hold, the BoD will engage in live Q&A.

Anyway, the key to success is payor coverage, all eyes are on US CMS coverage now. When and if that gets achieved I would buy back in, yes it will be higher but there is still too much uncertainty. SHL deal is contingent on milestones, I wonder if CMS is part of that..